Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 20/20 | 0.80 |
| ▸ | HDAC4 | P56524 | 20/20 | 0.80 |
| ▸ | HDAC1 | Q13547 | 20/20 | 0.80 |
| ▸ | HDAC7 | Q8WUI4 | 20/20 | 0.80 |
| ▸ | HDAC2 | Q92769 | 20/20 | 0.80 |
| ▸ | HDAC10 | Q969S8 | 20/20 | 0.80 |
| ▸ | HDAC11 | Q96DB2 | 20/20 | 0.80 |
| ▸ | HDAC8 | Q9BY41 | 20/20 | 0.80 |
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 0.80 |
| ▸ | HDAC9 | Q9UKV0 | 20/20 | 0.80 |
| ▸ | HDAC5 | Q9UQL6 | 20/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1011960 | 0.89 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1011818 | 0.87 | HDAC3 (0.77) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1011619 | 0.86 | HDAC3 (0.61) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1011959 | 0.86 | HDAC3 (0.80) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1012598 | 0.85 | HDAC3 (0.79) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1010626 | 0.84 | HDAC3 (0.80) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1011662 | 0.84 | HDAC3 (0.66) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1012456 | 0.84 | HDAC3 (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1012170 | 0.83 | HDAC3 (0.78) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1011731 | 0.83 | HDAC3 (0.80) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881977-B1 | HISTONE DEACETYLASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-01-05 | — | — | EP | claimed |
| US-20100152155-A1 | Histone Deacetylase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2010-06-17 | — | — | US | claimed |
| EP-1881977-A1 | HISTONE DEACETYLASE INHIBITORS | Chroma Therapeutics Limited (GB) | 2008-01-30 | — | — | EP | claimed |
| WO-2006123121-A1 | HISTONE DEACETYLASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-23 | — | — | WO | claimed |
| US-7932246-B2 | Histone deacetylase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-04-26 | — | — | US | disclosed |
| EP-1881977-B1 | HISTONE DEACETYLASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-01-05 | — | — | EP | disclosed |
| US-20100152155-A1 | Histone Deacetylase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2010-06-17 | — | — | US | disclosed |
| EP-1881977-A1 | HISTONE DEACETYLASE INHIBITORS | Chroma Therapeutics Limited (GB) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006123121-A1 | HISTONE DEACETYLASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152155-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC2, HDAC11 | HDAC3 6/4885HDAC4 7/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.